Avidity Biosciences stock crossed below its 200-day average

Published on 10/14/2026 at 03:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Avidity Biosciences stock sat below its 200-day average October 7, 2026. Second-quarter revenue hit USD 3.00 million versus USD 0.67 million.

Stock technicals and earnings figures

Avidity Biosciences stock moved below its 200-day average on October 7, 2026.
Second-quarter revenue reached USD 3.00 million against USD 0.67 million consensus.
MarketBeat reported a Hold consensus and a USD 63.75 average target on October 7, 2026.

RNA, US05370A1088, Illustration mit AI erstellt.

Avidity Biosciences stock sat below its 200-day average on October 7, 2026, after trading as low as USD 7.78 against the USD 12.37 moving-average level, according to MarketBeat. The report identified Avidity Biosciences as a Nasdaq-listed biotechnology company under ticker RNA and placed its recent trading level near USD 7.99.

Three dated signals for RNA

On June 18, 2026, Cantor Fitzgerald began coverage with an Overweight rating and a USD 25.00 price target, according to MarketBeat. On August 13, 2026, the company reported second-quarter revenue of USD 3.00 million and a loss of USD 1.18 per share, compared with consensus revenue of USD 0.67 million and an expected loss of USD 1.42 per share.

On August 14, 2026, HC Wainwright reiterated a Buy rating and a USD 25.00 target, while the analyst group tracked by MarketBeat showed one Strong Buy, three Buy, eleven Hold and one Sell rating.

What does the break show

The technical gap matters because the USD 7.78 low was 37.11 percent below the USD 12.37 200-day average on October 7, 2026. The same report placed the average analyst target at USD 63.75, while the company had a market capitalization of USD 136.71 million on that date.

The earnings comparison was more favorable than the loss alone suggests. Second-quarter revenue of USD 3.00 million exceeded the USD 0.67 million consensus by USD 2.33 million, while the USD 1.18 loss per share was USD 0.24 narrower than the expected USD 1.42 loss.

RNA remains a clinical-stage biotech

Avidity develops antibody oligonucleotide conjugates, or AOCs, designed to combine antibody targeting with oligonucleotide medicines for genetic diseases. Its programs address myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy, according to MarketBeat.

Market value sets the reference

The market value stood at USD 136.71 million on October 7, 2026. The combination of a USD 12.37 technical average, USD 3.00 million quarterly revenue and a USD 63.75 consensus target leaves the stock defined by clinical execution and valuation dispersion rather than by current profitability.

Market context: Market report S&P 500.